Combined with a PD-1 monoclonal antibody (αPD-1) to block PD-1/PD-L1-mediated tumor immune escape, we investigated the efficacy against residual tumors after local iRFA and the impact on systemic antitumor immunity. Here, PDCD1 is linked to neoplasm.